FDA Will Relax Premarket Requirements To Enable LVAD Randomized Trials
This article was originally published in The Gray Sheet
Executive Summary
Randomized, controlled trials supporting PMAs for left-ventricular assist devices as destination therapy should compare the investigational device with an already approved LVAD, according to FDA